Jilin Aodong Pharmaceutical Group Co., Ltd. (SHE:000623)
China · Delayed Price · Currency is CNY 18.94
+0.06 (0.32%)
Feb 3, 2026, 9:55 AM CST
SHE:000623 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,268 | 2,537 | 3,404 | 2,850 | 2,263 | 2,237 |
Other Revenue | 73.86 | 73.86 | 45.58 | 17.95 | 41.05 | 15.11 |
| 2,341 | 2,611 | 3,449 | 2,868 | 2,304 | 2,252 | |
Revenue Growth (YoY) | -22.08% | -24.31% | 20.25% | 24.50% | 2.31% | -27.09% |
Cost of Revenue | 1,309 | 1,602 | 1,768 | 1,417 | 1,111 | 929.01 |
Gross Profit | 1,032 | 1,008 | 1,681 | 1,451 | 1,193 | 1,323 |
Selling, General & Admin | 1,062 | 1,055 | 1,354 | 1,181 | 1,093 | 1,279 |
Research & Development | 78 | 82.2 | 124.98 | 85.68 | 49.42 | 67.21 |
Other Operating Expenses | 58.34 | 37.28 | 46.43 | 42.77 | 39.3 | 43.02 |
Operating Expenses | 1,182 | 1,169 | 1,546 | 1,321 | 1,187 | 1,388 |
Operating Income | -149.97 | -160.4 | 134.53 | 129.91 | 5.87 | -65.74 |
Interest Expense | -51.55 | -92.08 | -144.35 | -142.99 | -130.49 | -126.82 |
Interest & Investment Income | 2,634 | 1,877 | 1,382 | 1,697 | 2,070 | 1,916 |
Other Non Operating Income (Expenses) | -12.59 | 7.42 | 107.65 | 589.79 | -7.62 | -5.28 |
EBT Excluding Unusual Items | 2,420 | 1,632 | 1,479 | 2,274 | 1,937 | 1,718 |
Impairment of Goodwill | - | - | - | - | - | -24.28 |
Gain (Loss) on Sale of Investments | 194 | -121.67 | -111.06 | -632.66 | -259.53 | -75.98 |
Gain (Loss) on Sale of Assets | -0.47 | -0.67 | 36.16 | 3.16 | -0.94 | -0.64 |
Asset Writedown | -79.62 | -65.33 | -3.25 | -1.25 | -2.84 | -1.25 |
Other Unusual Items | 77.54 | 77.54 | 98.83 | 77.92 | 92.6 | 100.79 |
Pretax Income | 2,612 | 1,521 | 1,500 | 1,721 | 1,767 | 1,717 |
Income Tax Expense | 55.56 | 2.23 | 55.83 | -80.16 | -4.19 | 25.14 |
Earnings From Continuing Operations | 2,556 | 1,519 | 1,444 | 1,801 | 1,771 | 1,691 |
Minority Interest in Earnings | 11.8 | 32.2 | 15.54 | -20.2 | 9.64 | 17.46 |
Net Income | 2,568 | 1,551 | 1,460 | 1,781 | 1,781 | 1,709 |
Net Income to Common | 2,568 | 1,551 | 1,460 | 1,781 | 1,781 | 1,709 |
Net Income Growth | 79.60% | 6.27% | -18.02% | 0.02% | 4.19% | 21.75% |
Shares Outstanding (Basic) | 1,178 | 1,177 | 1,125 | 1,135 | 1,139 | 1,158 |
Shares Outstanding (Diluted) | 1,178 | 1,177 | 1,295 | 1,301 | 1,259 | 1,276 |
Shares Change (YoY) | -7.34% | -9.08% | -0.46% | 3.36% | -1.39% | -0.28% |
EPS (Basic) | 2.18 | 1.32 | 1.30 | 1.57 | 1.56 | 1.48 |
EPS (Diluted) | 2.18 | 1.32 | 1.23 | 1.47 | 1.51 | 1.43 |
EPS Growth | 77.78% | 7.39% | -16.35% | -2.93% | 5.70% | 20.92% |
Free Cash Flow | 128.76 | -214.5 | -351.46 | 152.89 | 11.54 | 163.02 |
Free Cash Flow Per Share | 0.11 | -0.18 | -0.27 | 0.12 | 0.01 | 0.13 |
Dividend Per Share | 0.500 | 0.500 | 0.600 | 0.300 | 0.300 | 0.200 |
Dividend Growth | -37.50% | -16.67% | 100.00% | - | 50.00% | - |
Gross Margin | 44.09% | 38.62% | 48.74% | 50.59% | 51.76% | 58.74% |
Operating Margin | -6.40% | -6.14% | 3.90% | 4.53% | 0.26% | -2.92% |
Profit Margin | 109.67% | 59.43% | 42.33% | 62.09% | 77.29% | 75.89% |
Free Cash Flow Margin | 5.50% | -8.22% | -10.19% | 5.33% | 0.50% | 7.24% |
EBITDA | 56.34 | 45.48 | 339.83 | 326.49 | 200.39 | 129.73 |
EBITDA Margin | 2.41% | 1.74% | 9.85% | 11.38% | 8.70% | 5.76% |
D&A For EBITDA | 206.31 | 205.88 | 205.3 | 196.58 | 194.53 | 195.46 |
EBIT | -149.97 | -160.4 | 134.53 | 129.91 | 5.87 | -65.74 |
EBIT Margin | -6.40% | -6.14% | 3.90% | 4.53% | 0.26% | -2.92% |
Effective Tax Rate | 2.13% | 0.15% | 3.72% | - | - | 1.47% |
Revenue as Reported | 2,341 | 2,611 | 3,449 | 2,868 | 2,304 | 2,252 |
Advertising Expenses | - | 183.98 | 277.99 | 202.59 | 160.73 | 212.53 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.